nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—Vestibular disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0392	0.0392	CcSEcCtD
Sibutramine—Septicemia—Cyclosporine—focal segmental glomerulosclerosis	0.0346	0.0346	CcSEcCtD
Sibutramine—Rheumatoid arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.026	0.026	CcSEcCtD
Sibutramine—Carcinoma—Cyclosporine—focal segmental glomerulosclerosis	0.026	0.026	CcSEcCtD
Sibutramine—Goitre—Cyclosporine—focal segmental glomerulosclerosis	0.022	0.022	CcSEcCtD
Sibutramine—Bursitis—Cyclosporine—focal segmental glomerulosclerosis	0.0163	0.0163	CcSEcCtD
Sibutramine—Ear disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0146	0.0146	CcSEcCtD
Sibutramine—Gastric ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.0135	0.0135	CcSEcCtD
Sibutramine—Cerebration impaired—Cyclosporine—focal segmental glomerulosclerosis	0.0134	0.0134	CcSEcCtD
Sibutramine—Libido increased—Cyclosporine—focal segmental glomerulosclerosis	0.0129	0.0129	CcSEcCtD
Sibutramine—Psoriasis—Cyclosporine—focal segmental glomerulosclerosis	0.0125	0.0125	CcSEcCtD
Sibutramine—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0121	0.0121	CcSEcCtD
Sibutramine—Tooth disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0121	0.0121	CcSEcCtD
Sibutramine—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0115	0.0115	CcSEcCtD
Sibutramine—Myopathy—Cyclosporine—focal segmental glomerulosclerosis	0.0112	0.0112	CcSEcCtD
Sibutramine—Hyperlipidaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0109	0.0109	CcSEcCtD
Sibutramine—Tongue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0108	0.0108	CcSEcCtD
Sibutramine—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.0104	0.0104	CcSEcCtD
Sibutramine—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.0101	0.0101	CcSEcCtD
Sibutramine—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.01	0.01	CcSEcCtD
Sibutramine—Abscess—Cyclosporine—focal segmental glomerulosclerosis	0.00994	0.00994	CcSEcCtD
Sibutramine—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.00934	0.00934	CcSEcCtD
Sibutramine—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00921	0.00921	CcSEcCtD
Sibutramine—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.00907	0.00907	CcSEcCtD
Sibutramine—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00895	0.00895	CcSEcCtD
Sibutramine—Cardiovascular disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00895	0.00895	CcSEcCtD
Sibutramine—Rectal haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.0087	0.0087	CcSEcCtD
Sibutramine—Arthropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00864	0.00864	CcSEcCtD
Sibutramine—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00864	0.00864	CcSEcCtD
Sibutramine—Dysmenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00864	0.00864	CcSEcCtD
Sibutramine—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00864	0.00864	CcSEcCtD
Sibutramine—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.00853	0.00853	CcSEcCtD
Sibutramine—Glossitis—Cyclosporine—focal segmental glomerulosclerosis	0.00853	0.00853	CcSEcCtD
Sibutramine—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00847	0.00847	CcSEcCtD
Sibutramine—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.00842	0.00842	CcSEcCtD
Sibutramine—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.00826	0.00826	CcSEcCtD
Sibutramine—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00826	0.00826	CcSEcCtD
Sibutramine—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.008	0.008	CcSEcCtD
Sibutramine—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00772	0.00772	CcSEcCtD
Sibutramine—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.00772	0.00772	CcSEcCtD
Sibutramine—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.00759	0.00759	CcSEcCtD
Sibutramine—Nightmare—Cyclosporine—focal segmental glomerulosclerosis	0.00759	0.00759	CcSEcCtD
Sibutramine—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.00746	0.00746	CcSEcCtD
Sibutramine—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.00742	0.00742	CcSEcCtD
Sibutramine—Cramps of lower extremities—Cyclosporine—focal segmental glomerulosclerosis	0.00722	0.00722	CcSEcCtD
Sibutramine—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.00718	0.00718	CcSEcCtD
Sibutramine—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00711	0.00711	CcSEcCtD
Sibutramine—Abnormal vision—Cyclosporine—focal segmental glomerulosclerosis	0.00686	0.00686	CcSEcCtD
Sibutramine—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.00682	0.00682	CcSEcCtD
Sibutramine—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.00682	0.00682	CcSEcCtD
Sibutramine—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00669	0.00669	CcSEcCtD
Sibutramine—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00656	0.00656	CcSEcCtD
Sibutramine—Hepatic function abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00653	0.00653	CcSEcCtD
Sibutramine—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00644	0.00644	CcSEcCtD
Sibutramine—Vascular purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00638	0.00638	CcSEcCtD
Sibutramine—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00635	0.00635	CcSEcCtD
Sibutramine—Eye pain—Cyclosporine—focal segmental glomerulosclerosis	0.00632	0.00632	CcSEcCtD
Sibutramine—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.00621	0.00621	CcSEcCtD
Sibutramine—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00615	0.00615	CcSEcCtD
Sibutramine—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00607	0.00607	CcSEcCtD
Sibutramine—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.006	0.006	CcSEcCtD
Sibutramine—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.00597	0.00597	CcSEcCtD
Sibutramine—Purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00592	0.00592	CcSEcCtD
Sibutramine—Anaphylactoid reaction—Cyclosporine—focal segmental glomerulosclerosis	0.0059	0.0059	CcSEcCtD
Sibutramine—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00587	0.00587	CcSEcCtD
Sibutramine—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00585	0.00585	CcSEcCtD
Sibutramine—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00571	0.00571	CcSEcCtD
Sibutramine—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00566	0.00566	CcSEcCtD
Sibutramine—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00562	0.00562	CcSEcCtD
Sibutramine—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00562	0.00562	CcSEcCtD
Sibutramine—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.00541	0.00541	CcSEcCtD
Sibutramine—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00535	0.00535	CcSEcCtD
Sibutramine—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00523	0.00523	CcSEcCtD
Sibutramine—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00505	0.00505	CcSEcCtD
Sibutramine—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00503	0.00503	CcSEcCtD
Sibutramine—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.00496	0.00496	CcSEcCtD
Sibutramine—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.00493	0.00493	CcSEcCtD
Sibutramine—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00474	0.00474	CcSEcCtD
Sibutramine—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.00461	0.00461	CcSEcCtD
Sibutramine—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00456	0.00456	CcSEcCtD
Sibutramine—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00449	0.00449	CcSEcCtD
Sibutramine—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00445	0.00445	CcSEcCtD
Sibutramine—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00442	0.00442	CcSEcCtD
Sibutramine—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00438	0.00438	CcSEcCtD
Sibutramine—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00433	0.00433	CcSEcCtD
Sibutramine—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00432	0.00432	CcSEcCtD
Sibutramine—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00431	0.00431	CcSEcCtD
Sibutramine—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00431	0.00431	CcSEcCtD
Sibutramine—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00429	0.00429	CcSEcCtD
Sibutramine—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.00427	CcSEcCtD
Sibutramine—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.00427	CcSEcCtD
Sibutramine—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00419	0.00419	CcSEcCtD
Sibutramine—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00415	0.00415	CcSEcCtD
Sibutramine—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00413	0.00413	CcSEcCtD
Sibutramine—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00397	0.00397	CcSEcCtD
Sibutramine—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.00396	0.00396	CcSEcCtD
Sibutramine—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00395	0.00395	CcSEcCtD
Sibutramine—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00393	0.00393	CcSEcCtD
Sibutramine—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.00392	0.00392	CcSEcCtD
Sibutramine—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.0038	0.0038	CcSEcCtD
Sibutramine—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.00368	0.00368	CcSEcCtD
Sibutramine—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00358	0.00358	CcSEcCtD
Sibutramine—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00354	0.00354	CcSEcCtD
Sibutramine—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.00353	0.00353	CcSEcCtD
Sibutramine—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00349	0.00349	CcSEcCtD
Sibutramine—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00344	0.00344	CcSEcCtD
Sibutramine—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00339	0.00339	CcSEcCtD
Sibutramine—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.00337	0.00337	CcSEcCtD
Sibutramine—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00337	0.00337	CcSEcCtD
Sibutramine—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00334	0.00334	CcSEcCtD
Sibutramine—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.0033	0.0033	CcSEcCtD
Sibutramine—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00324	0.00324	CcSEcCtD
Sibutramine—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00322	0.00322	CcSEcCtD
Sibutramine—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00319	0.00319	CcSEcCtD
Sibutramine—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00318	0.00318	CcSEcCtD
Sibutramine—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00316	0.00316	CcSEcCtD
Sibutramine—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.00314	0.00314	CcSEcCtD
Sibutramine—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.0031	0.0031	CcSEcCtD
Sibutramine—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.00309	0.00309	CcSEcCtD
Sibutramine—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00308	0.00308	CcSEcCtD
Sibutramine—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.003	0.003	CcSEcCtD
Sibutramine—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00298	0.00298	CcSEcCtD
Sibutramine—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00297	0.00297	CcSEcCtD
Sibutramine—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00293	0.00293	CcSEcCtD
Sibutramine—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00293	0.00293	CcSEcCtD
Sibutramine—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00293	0.00293	CcSEcCtD
Sibutramine—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00292	0.00292	CcSEcCtD
Sibutramine—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00289	0.00289	CcSEcCtD
Sibutramine—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00286	0.00286	CcSEcCtD
Sibutramine—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00283	0.00283	CcSEcCtD
Sibutramine—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.0028	0.0028	CcSEcCtD
Sibutramine—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.0028	0.0028	CcSEcCtD
Sibutramine—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00279	0.00279	CcSEcCtD
Sibutramine—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00275	0.00275	CcSEcCtD
Sibutramine—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00272	0.00272	CcSEcCtD
Sibutramine—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00271	0.00271	CcSEcCtD
Sibutramine—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00267	0.00267	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00256	0.00256	CcSEcCtD
Sibutramine—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00254	0.00254	CcSEcCtD
Sibutramine—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00252	0.00252	CcSEcCtD
Sibutramine—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.0025	0.0025	CcSEcCtD
Sibutramine—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00249	0.00249	CcSEcCtD
Sibutramine—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00247	0.00247	CcSEcCtD
Sibutramine—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00244	0.00244	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00242	0.00242	CcSEcCtD
Sibutramine—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.0024	0.0024	CcSEcCtD
Sibutramine—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.0024	0.0024	CcSEcCtD
Sibutramine—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00231	0.00231	CcSEcCtD
Sibutramine—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00229	0.00229	CcSEcCtD
Sibutramine—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.00223	0.00223	CcSEcCtD
Sibutramine—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00222	0.00222	CcSEcCtD
Sibutramine—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00222	0.00222	CcSEcCtD
Sibutramine—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00207	0.00207	CcSEcCtD
Sibutramine—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00201	0.00201	CcSEcCtD
Sibutramine—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.00198	CcSEcCtD
Sibutramine—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00192	0.00192	CcSEcCtD
Sibutramine—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00185	0.00185	CcSEcCtD
Sibutramine—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.00178	CcSEcCtD
Sibutramine—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00177	0.00177	CcSEcCtD
Sibutramine—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00177	0.00177	CcSEcCtD
Sibutramine—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00176	0.00176	CcSEcCtD
Sibutramine—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00167	0.00167	CcSEcCtD
